Triplet Immunotherapy Shows Promise in Early-Phase Trial of Untreated Advanced Melanoma

Source: ASCO Daily News, June 2024

The triplet combination of nivolumab, relatlimab, and ipilimumab offered promising response rates and survival outcomes in patients with untreated advanced melanoma, according to preliminary data from the nonrandomized phase 1/2 RELATIVITY-048 trial (Abstract 9504). Although the results require confirmation in larger randomized trials, the 4-year overall survival (OS) rate seen with the triplet regimen compares favorably with other nivolumab-based combinations in this setting.

Paolo Antonio Ascierto, MD, of the Istituto Nazionale dei Tumori IRCCS in Naples, Italy, who presented the study results at the 2024 ASCO Annual Meeting, called the efficacy “very promising.”

Abstract Discussant Sunandana Chandra, MD, MS, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, agreed that the triplet has strong potential, although more work is needed.
READ THE ORIGINAL FULL ARTICLE